Mustang Bio Announced That Updated Data From The Ongoing Phase 1/2 Trial Of MB-106 CAR T Cell Therapy, Show A Favorable Safety And Efficacy Profile In Patients With Waldenstrom Macroglobulinemia, A Rare Form Of Blood Cancer
Portfolio Pulse from Benzinga Newsdesk
Mustang Bio announced updated data from the ongoing Phase 1/2 trial of MB-106 CAR T cell therapy, showing a favorable safety and efficacy profile in patients with Waldenstrom Macroglobulinemia, a rare form of blood cancer.
June 12, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mustang Bio's MB-106 CAR T cell therapy demonstrates favorable safety and efficacy in Phase 1/2 trial for Waldenstrom Macroglobulinemia.
The positive results from the ongoing Phase 1/2 trial of MB-106 CAR T cell therapy indicate a favorable safety and efficacy profile in patients with Waldenstrom Macroglobulinemia. This news is likely to have a positive impact on Mustang Bio's stock price in the short term, as it demonstrates the potential of their therapy in treating a rare form of blood cancer.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100